Patent: 10,280,208
✉ Email this page to a colleague
Summary for Patent: 10,280,208
Title: | TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies |
Abstract: | Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided. |
Inventor(s): | Zang; Xingxing (New York, NY), Chinai; Jordan M. (Bronx, NY), Janakiram; Murali (Brooklyn, NY), Almo; Steven C. (Pelham, NY), Fiser; Andras (New York, NY) |
Assignee: | Albert Einstein College of Medicine (Bronx, NY) |
Application Number: | 15/300,294 |
Patent Claims: | see list of patent claims |
Details for Patent 10,280,208
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Csl Behring Ag | CARIMUNE, CARIMUNE NF, PANGLOBULIN, SANDOGLOBULIN | immune globulin intravenous (human) | For Injection | 102367 | 07/27/2000 | ⤷ Try a Trial | 2034-04-30 |
Csl Behring Ag | PRIVIGEN | immune globulin intravenous (human), 10% liquid | Injection | 125201 | 07/26/2007 | ⤷ Try a Trial | 2034-04-30 |
Csl Behring Ag | PRIVIGEN | immune globulin intravenous (human), 10% liquid | Injection | 125201 | 10/02/2009 | ⤷ Try a Trial | 2034-04-30 |
Csl Behring Ag | PRIVIGEN | immune globulin intravenous (human), 10% liquid | Injection | 125201 | 02/07/2013 | ⤷ Try a Trial | 2034-04-30 |
Bio Products Laboratory | GAMMAPLEX | immune globulin intravenous (human) | Injection | 125329 | 09/17/2009 | ⤷ Try a Trial | 2034-04-30 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |